Deficiency in STAT1 Signaling Predisposes Gut Inflammation and Prompts Colorectal Cancer Development

Signal transducer and activator of transcription 1 (STAT1) is part of the Janus kinase (JAK/STAT) signaling pathway that controls critical events in intestinal immune function related to innate and adaptive immunity. Recent studies have implicated STAT1 in tumor–stroma interactions, and its expression and activity are perturbed during colon cancer. However, the role of STAT1 during the initiation of inflammation-associated cancer is not clearly understood. To determine the role of STAT1 in colitis-associated colorectal cancer (CAC), we analyzed the tumor development and kinetics of cell recruitment in wild-type WT or STAT1−/− mice treated with azoxymethane (AOM) and dextran sodium sulfate (DSS). Following CAC induction, STAT1−/− mice displayed an accelerated appearance of inflammation and tumor formation, and increased damage and scores on the disease activity index (DAI) as early as 20 days after AOM-DSS exposure compared to their WT counterparts. STAT1−/− mice showed elevated colonic epithelial cell proliferation in early stages of injury-induced tumor formation and decreased apoptosis in advanced tumors with over-expression of the anti-apoptotic protein Bcl2 at the colon. STAT1−/− mice showed increased accumulation of Ly6G+Ly6C−CD11b+ cells in the spleen at 20 days of CAC development with concomitant increases in the production of IL-17A, IL-17F, and IL-22 cytokines compared to WT mice. Our findings suggest that STAT1 plays a role as a tumor suppressor molecule in inflammation-associated carcinogenesis, particularly during the very early stages of CAC initiation, modulating immune responses as well as controlling mechanisms such as apoptosis and cell proliferation.

[1]  J. Kovarik,et al.  Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. , 2003, International journal of molecular medicine.

[2]  Seiya Kato,et al.  IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice , 2006, The Journal of experimental medicine.

[3]  R. Moriggl,et al.  Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma , 2013, British Journal of Cancer.

[4]  C. A. de la Motte,et al.  Hyaluronan-Mediated Leukocyte Adhesion and Dextran Sulfate Sodium-Induced Colitis Are Attenuated in the Absence of Signal Transducer and Activator of Transcription 1 , 2008 .

[5]  R. Morita,et al.  SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-γ and IL-17A production , 2011, The Journal of experimental medicine.

[6]  A. Chong,et al.  IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. , 1998, Cancer research.

[7]  A. Abbas,et al.  STAT1-Activating Cytokines Limit Th17 Responses through Both T-bet–Dependent and –Independent Mechanisms , 2010, The Journal of Immunology.

[8]  E. Pamer,et al.  Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.

[9]  Chilakamarti V. Ramana,et al.  Stat1-dependent and -independent pathways in IFN-γ-dependent signaling , 2002 .

[10]  Robin P Boushey,et al.  Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. , 2009, Clinics in colon and rectal surgery.

[11]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[12]  K. Hirakawa,et al.  Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. , 2015, World journal of gastroenterology.

[13]  A. Giordano,et al.  From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives. , 2016, Anticancer research.

[14]  K. Kudsk,et al.  JAK-STAT and intestinal mucosal immunology , 2013, JAK-STAT.

[15]  Mathias Müller,et al.  The good and the bad faces of STAT1 in solid tumours. , 2017, Cytokine.

[16]  S. M. Toor,et al.  Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients , 2016, Front. Immunol..

[17]  R. Young,et al.  Hematopoietic Remodeling in Interferon-γ–Deficient Mice Infected With Mycobacteria , 1998 .

[18]  R. Beelen,et al.  The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential. , 2017, Immunobiology.

[19]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[20]  R. Kiesslich,et al.  Activation Pattern of Signal Transducers and Activators of Transcription (STAT) Factors in Inflammatory Bowel Diseases , 2005, The American Journal of Gastroenterology.

[21]  G. Stark,et al.  Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. , 2002, Trends in immunology.

[22]  J. Hampe,et al.  Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease , 2002, Gut.

[23]  T. Urich,et al.  Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis , 2015, The Journal of Immunology.

[24]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[25]  Luis E. Arias-Romero,et al.  Lack of STAT6 Attenuates Inflammation and Drives Protection against Early Steps of Colitis-Associated Colon Cancer , 2017, Cancer Immunology Research.

[26]  Y. Ben-Neriah,et al.  Inflammatory networks underlying colorectal cancer , 2016, Nature Immunology.

[27]  Greta Volpedo,et al.  STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade , 2017, Oncoimmunology.

[28]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[29]  A. Jayakumar,et al.  Stat6 Promotes Intestinal Tumorigenesis in a Mouse Model of Adenomatous Polyposis by Expansion of MDSCs and Inhibition of Cytotoxic CD8 Response , 2017, Neoplasia.

[30]  R. Kastelein,et al.  Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. , 2007, Annual review of immunology.

[31]  A. Koromilas,et al.  The tumor suppressor function of STAT1 in breast cancer , 2013, JAK-STAT.

[32]  Martha L Slattery,et al.  JAK/STAT/SOCS‐signaling pathway and colon and rectal cancer , 2013, Molecular carcinogenesis.

[33]  Jianqiu Chen,et al.  Differential Expression of STAT1 and p21 Proteins Predicts Pancreatic Cancer Progression and Prognosis , 2014, Pancreas.

[34]  IL-22 is related to development of human colon cancer by activation of STAT3 , 2013, BMC Cancer.

[35]  L. Augenlicht,et al.  The Role of STAT1 for Crosstalk between Fibroblasts and Colon Cancer Cells , 2014, Front. Oncol..

[36]  L. Cosmi,et al.  Evidence for a cross-talk between human neutrophils and Th17 cells. , 2010, Blood.

[37]  H. Cooper,et al.  Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions , 2007, Acta Pharmacologica Sinica.

[38]  W. Khan,et al.  Investigating intestinal inflammation in DSS-induced model of IBD. , 2012, Journal of visualized experiments : JoVE.

[39]  S. Rose-John,et al.  The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth , 2016, Oncotarget.

[40]  A. Ashkenazi,et al.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors , 2017, Nature Reviews Drug Discovery.

[41]  Jie Huang,et al.  Oncogenic Ki-Ras Inhibits the Expression of Interferon-responsive Genes through Inhibition of STAT1 and STAT2 Expression* , 2003, Journal of Biological Chemistry.

[42]  L. Klampfer.  The role of signal transducers and activators of transcription in colon cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[43]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[44]  S. Itzkowitz,et al.  Intestinal inflammation and cancer. , 2011, Gastroenterology.

[45]  M. Ilyas,et al.  Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer , 2010, Gut.

[46]  C. Bucana,et al.  Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells , 2002, Oncogene.

[47]  M. Neurath,et al.  Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer , 2016, Vaccines.

[48]  J. Gisbert,et al.  Systematic review with meta‐analysis: the declining risk of colorectal cancer in ulcerative colitis , 2014, Alimentary pharmacology & therapeutics.

[49]  T. Muto,et al.  Ulcerative colitis‐associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: A nationwide Japanese study , 2011, Inflammatory bowel diseases.

[50]  D. Han,et al.  Role of IL-17A in the development of colitis-associated cancer. , 2011, Carcinogenesis.

[51]  M. Feuerer,et al.  Monocytes and Macrophages in Cancer: Development and Functions , 2013, Cancer Microenvironment.

[52]  Qiang Xu,et al.  Selective Sequestration of STAT1 in the Cytoplasm via Phosphorylated SHP-2 Ameliorates Murine Experimental Colitis , 2012, The Journal of Immunology.

[53]  G. Ferbeyre,et al.  Tumour-promoting role of SOCS1 in colorectal cancer cells , 2015, Scientific Reports.

[54]  D. Zelterman,et al.  Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis , 2010, Proceedings of the National Academy of Sciences.

[55]  R. Lai,et al.  The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma , 2014, BMC Cancer.